How do Kontoor Brands, Inc. and ResMed compare by revenue?

Kontoor Brands, Inc. reported revenue of $853.2M in Q3 FY2025, while ResMed reported $1.4B in Q4 FY2026. ResMed is 1.7× larger by last-quarter revenue.

Which is growing revenue faster, Kontoor Brands, Inc. or ResMed?

Kontoor Brands, Inc.'s latest revenue grew 27.3% year-over-year, versus 11.0% for ResMed. Kontoor Brands, Inc. is growing faster on a YoY basis.

Which has a higher gross margin, Kontoor Brands, Inc. or ResMed?

Kontoor Brands, Inc.'s gross margin is 41.3% vs ResMed's 61.8%. ResMed converts more of each revenue dollar into gross profit.

Which has a higher net margin, Kontoor Brands, Inc. or ResMed?

Kontoor Brands, Inc.'s net margin is 4.3% vs ResMed's 27.6%. ResMed has the higher bottom-line margin.

What is the 2-year revenue CAGR for Kontoor Brands, Inc. vs ResMed?

Over the trailing 8 quarters, Kontoor Brands, Inc. compounded revenue at roughly 14.2% per year, versus 7.8% for ResMed. Kontoor Brands, Inc. has the faster medium-term growth trajectory.

Where does this KTB vs RMD data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of Kontoor Brands, Inc. (KTB) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $853.2M, roughly 1.7× Kontoor Brands, Inc.). ResMed runs the higher net margin — 27.6% vs 4.3%, a 23.3% gap on every dollar of revenue. On growth, Kontoor Brands, Inc. posted the faster year-over-year revenue change (27.3% vs 11.0%). Over the past eight quarters, Kontoor Brands, Inc.'s revenue compounded faster (14.2% CAGR vs 7.8%).

Kontoor Brands, Inc.KTBEarnings & Financial Report

NYSE · Consumer Discretionary · Men's & Boys' Furnishgs, Work Clothg, & Allied Garments

Kontoor Brands is an American clothing company. It was a spin off from the VF Corporation in May 2019, and markets clothing under the Lee, Wrangler and Helly Hansen brand names.

ResMedRMDEarnings & Financial Report

NYSE · Health Care · Health Care Equipment

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

KTB vs RMD — Head-to-Head

Bigger by revenue

RMD

1.7× larger

$1.4B

$853.2M

Growing faster (revenue YoY)

KTB

+16.3% gap

27.3%

11.0%

Higher net margin

RMD

23.3% more per $

27.6%

4.3%

Faster 2-yr revenue CAGR

KTB

Annualised

14.2%

7.8%

Income Statement — Q3 FY2025 vs Q4 FY2026

Metric	KTB	RMD
Revenue	$853.2M	$1.4B
Net Profit	$36.9M	$392.6M
Gross Margin	41.3%	61.8%
Operating Margin	7.5%	34.6%
Net Margin	4.3%	27.6%
Revenue YoY	27.3%	11.0%
Net Profit YoY	-47.6%	13.9%
EPS (diluted)	$0.66	$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

KTB

RMD

Q2 26	—	$1.4B
Q1 26	—	$1.4B
Q4 25	—	$1.4B
Q3 25	$853.2M	$1.3B
Q2 25	$658.3M	$1.3B
Q1 25	$622.9M	$1.3B
Q4 24	$699.3M	$1.3B
Q3 24	$670.2M	$1.2B

Net Profit

KTB

RMD

Q2 26	—	$392.6M
Q1 26	—	$398.7M
Q4 25	—	$392.6M
Q3 25	$36.9M	$348.5M
Q2 25	$73.9M	$379.7M
Q1 25	$42.9M	$365.0M
Q4 24	$64.0M	$344.6M
Q3 24	$70.5M	$311.4M

Gross Margin

KTB

RMD

Q2 26	—	61.8%
Q1 26	—	62.2%
Q4 25	—	61.8%
Q3 25	41.3%	61.5%
Q2 25	46.3%	60.8%
Q1 25	47.5%	59.3%
Q4 24	43.7%	58.6%
Q3 24	44.7%	58.6%

Operating Margin

KTB

RMD

Q2 26	—	34.6%
Q1 26	—	34.9%
Q4 25	—	34.6%
Q3 25	7.5%	33.4%
Q2 25	11.9%	33.7%
Q1 25	11.8%	33.0%
Q4 24	12.1%	32.5%
Q3 24	14.7%	31.6%

Net Margin

KTB

RMD

Q2 26	—	27.6%
Q1 26	—	27.9%
Q4 25	—	27.6%
Q3 25	4.3%	26.1%
Q2 25	11.2%	28.2%
Q1 25	6.9%	28.3%
Q4 24	9.1%	26.9%
Q3 24	10.5%	25.4%

EPS (diluted)

KTB

RMD

Q2 26	—	$2.68
Q1 26	—	$2.74
Q4 25	—	$2.68
Q3 25	$0.66	$2.37
Q2 25	$1.32	$2.58
Q1 25	$0.76	$2.48
Q4 24	$1.13	$2.34
Q3 24	$1.26	$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	KTB	RMD
Cash + ST InvestmentsLiquidity on hand	$82.4M	$1.4B
Total DebtLower is stronger	$1.3B	$663.8M
Stockholders' EquityBook value	$529.6M	$6.3B
Total Assets	$2.9B	$8.5B
Debt / EquityLower = less leverage	2.53×	0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

KTB

RMD

Q2 26	—	$1.4B
Q1 26	—	$1.7B
Q4 25	—	$1.4B
Q3 25	$82.4M	$1.4B
Q2 25	$107.5M	$1.2B
Q1 25	$356.7M	$932.7M
Q4 24	$334.1M	$521.9M
Q3 24	$269.4M	$426.4M

Total Debt

KTB

RMD

Q2 26	—	$663.8M
Q1 26	—	$664.1M
Q4 25	—	$403.9M
Q3 25	$1.3B	$408.7M
Q2 25	$1.4B	$658.4M
Q1 25	$735.6M	$663.1M
Q4 24	$740.3M	$662.9M
Q3 24	$745.0M	$667.6M

Stockholders' Equity

KTB

RMD

Q2 26	—	$6.3B
Q1 26	—	$6.5B
Q4 25	—	$6.3B
Q3 25	$529.6M	$6.1B
Q2 25	$498.3M	$6.0B
Q1 25	$426.7M	$5.5B
Q4 24	$400.1M	$5.3B
Q3 24	$356.9M	$5.2B

Total Assets

KTB

RMD

Q2 26	—	$8.5B
Q1 26	—	$8.8B
Q4 25	—	$8.5B
Q3 25	$2.9B	$8.3B
Q2 25	$2.7B	$8.2B
Q1 25	$1.7B	$7.6B
Q4 24	$1.7B	$7.1B
Q3 24	$1.7B	$7.2B

Debt / Equity

KTB

RMD

Q2 26	—	0.11×
Q1 26	—	0.10×
Q4 25	—	0.06×
Q3 25	2.53×	0.07×
Q2 25	2.74×	0.11×
Q1 25	1.72×	0.12×
Q4 24	1.85×	0.13×
Q3 24	2.09×	0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	KTB	RMD
Operating Cash FlowLast quarter	$64.1M	—
Free Cash FlowOCF − Capex	$55.8M	—
FCF MarginFCF / Revenue	6.5%	—
Capex IntensityCapex / Revenue	1.0%	—
Cash ConversionOCF / Net Profit	1.74×	—
TTM Free Cash FlowTrailing 4 quarters	$228.0M	—